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ABSTRACT
Introduction Primary ciliary dyskinesia (PCD) is a rare, 
genetic, multiorgan disease with an estimated prevalence 
of 1 in 10 000. It affects mainly the upper and lower 
airways due to impaired mucociliary clearance. Almost 
all patients have sinonasal or otologic (ear–nose–throat, 
ENT) problems, although the ENT clinical phenotype may 
present great variability. Despite that, data on PCD ENT 
manifestations are scarce and based on small single- 
centre studies. To date, we know little about the spectrum 
and severity of PCD ENT disease, its association with 
lung disease, its course over life and its determinants of 
prognosis.
This study protocol describes the aims and methods of the 
first prospective, observational, multinational cohort study 
focusing on ENT disease in patients with PCD.
Methods and analysis The ENT prospective international 
cohort of patients with PCD (EPIC- PCD) is a prospective 
standardised observational clinical cohort set up as a 
multinational multicentre study, embedded into routine 
patient care. It aims to longitudinally characterise ENT 
disease in patients with PCD and its association with lung 
disease, and to identify determinants of its prognosis. 
Patients of all ages, diagnosed with PCD who undergo an 
ENT clinical assessment at least once a year at one of the 
participating centres will be invited to participate. Collected 
data include diagnostic test results, results of ENT 
examinations, lung function measurements, information 
on management of ENT disease and patient- reported 
data on clinical symptoms and health- related quality of 
life (QoL). Data are collected using the standardised PCD- 
specific FOLLOW- PCD form and the validated QoL- PCD 
questionnaire.
Ethics and dissemination The study has been reviewed 
and approved by the Human Research Ethics Committees 
at all participating centres, based on local legislation. The 
results of the study will be published in scientific journals, 
presented at scientific conferences and disseminated to 
participants and national patient organisations.
Trial registration NCT04611516.
INTRODUCTION
Primary ciliary dyskinesia (PCD) is a rare 
genetic, multiorgan disorder affecting 
approximately 1:10 000 individuals.1 2 Muta-
tions in disease- causing genes result in defects 
in ciliary structure or function, leading to a 
wide range of symptoms from different organ 
systems.3–5 The clinical phenotype of the 
disease is heterogeneous; however, reduced 
airway mucociliary clearance predisposes 
almost all affected individuals to recurrent 
upper and lower respiratory infections.6 7
Strengths and limitations of this study
 ► The ear–nose–throat prospective international 
cohort of patients with primary ciliary dyskinesia 
(EPIC- PCD) is the first prospective international 
multicentre clinical study focusing on upper airways 
disease in patients with PCD.
 ► The study is embedded in routine patient care, 
which allows recruitment of large numbers of pa-
tients, necessary in rare diseases research.
 ► The study combines objective assessments of the 
upper airways and patient- reported information on 
symptoms and health- related quality of life (QoL), 
all collected with disease- specific tools, in a stan-
dardised way.
 ► The cohort aims to be representative of paediatric 
and adult patients with PCD, followed up at estab-
lished PCD clinical centres; however, it will not rep-
resent patients with atypical symptoms who remain 
undiagnosed or live in areas where diagnosis and 
care of PCD is not well established.
 ► The EPIC- PCD has the potential to become a valu-
able research resource in order to help understand 
better the disease and to improve diagnosis, clinical 
care and QoL of patients with PCD.
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Persistent symptoms from the upper airways and ears 
(ear–nose–throat: ENT) are a common characteristic of 
most patients with PCD. Ear symptoms commonly present 
in children with PCD as severe and bilateral otitis media 
with effusion (OME).8–11 OME usually resolves spon-
taneously in otherwise healthy children, but in PCD it 
seems to persist longer and might need specific manage-
ment.8 12–15 In some cases, persistent OME may lead to 
hearing impairment and cause delays in speech develop-
ment.16 17 A newly published study evaluated 47 children 
in two PCD centres in North America and found that 
52% of children with PCD- related hearing loss were not 
aware of their hearing deficit that was present on audio-
logical assessment.18 While otologic involvement seems to 
improve with age in patients with PCD, sinonasal disease 
appears to persist and may worsen in adulthood.19 First 
manifestations appear sometimes soon after birth and are 
usually non- specific in the form of rhinitis and episodic 
facial pain due to recurrent infections leading gradually 
to chronic rhinosinusitis (CRS).20–24 In adults, a recent 
study identified sinonasal disease as a primary cause of 
decreased quality of life (QoL) in patients with PCD.19 
Hypoplasia and agenesis of paranasal sinuses have also 
been described, while nasal polyps are more common in 
patients with PCD compared with the general population, 
although this complication has not been well character-
ised.19 25 26
Despite being so frequent and impairing patients’ 
physical health and QoL, data on ENT disease in PCD 
are still scarce. Several large national and multinational 
research collaborations have made important advances 
in PCD research in the recent years, though most clin-
ical studies focus on improving diagnosis and charac-
terising lung disease.27–30 Only few retrospective and 
single- centre studies have described ENT manifestations 
in some details. Most studies focused on children and 
little is known about age- related changes,8 13 while studies, 
including standardised sinonasal and otologic evalua-
tions, were rare. We lack knowledge about the spectrum 
and severity of ENT disease in patients with PCD, its asso-
ciation with lung disease, its course over life and determi-
nants of prognosis.
This study protocol describes the aims and methods of 
the first prospective, observational, multinational cohort 
study focusing on ENT disease in patients with PCD.
Study objectives
This study aims to characterise ENT disease in patients 
with PCD and its association with lung disease, and to 
identify determinants of its course and prognosis. Specif-
ically, we aim to: (a) assess the prevalence and severity 
of sinonasal and otologic symptoms and the frequency 
and range of signs and physiological findings assessed 
during standardised ENT physical examination, and 
describe possible differences by age; (b) study the associ-
ation of sinonasal and otologic disease with lung disease 
in patients with PCD and (c) identify determinants of the 




The ENT prospective international cohort of patients 
with PCD (EPIC- PCD) is a prospective observational clin-
ical cohort set up as a multinational multicentre study. 
It is embedded into routine patient care of participating 
reference centres for PCD and patients continue to be 
managed according to local procedures and protocols. 
The study is hosted at the Institute of Social and Preven-
tive Medicine (EPIC- PCD data centre) at the University of 
Bern, Switzerland, and is managed in collaboration with 
participating centres (EPIC- PCD clinics).
Patient data are collected prospectively. Baseline infor-
mation is collected at the enrolment of the patient in the 
study and follow- up data during clinical follow- up visits 
at the participating centres. The study has no foreseen 
endpoint. Patient follow- up is planned for a minimum 
period of 4 years; however, it will be extended if collabo-
rators agree.
Study population
Inclusion criteria and participating centres
Patients of all ages, diagnosed with PCD, according to 
the European Respiratory Society (ERS) guidelines, and 
followed- up at one of the participating centres, are invited 
to participate in the EPIC- PCD.27 Patients are excluded if 
they do not undergo an ENT clinical assessment at base-
line and at least once a year during the study period.
Patient recruitment has started at the following centres 
(EPIC- PCD clinics; figure 1):
 ► University Hospital Bicêtre Paris- Sud, France.
 ► Centre Hospitalier Intercommunal Creteil and 
University Hospital Henri Mondor, France.
 ► Hospital Universitario La Fe in Valencia, Spain.
 ► University Hospital of Southampton, UK.
 ► University Hospital of Leuven, Belgium.
 ► VU University Medical Center in Amsterdam, the 
Netherlands.
 ► University of Cyprus;
 ► Hacettepe University in Ankara, Turkey;
 ► Marmara University in Istanbul, Turkey;
 ► University Children’s Hospital Charité-Universitäts-
medizin in Berlin, Germany.
 ► University Children’s Hospital in Bern, Switzerland.
After the establishment of the study in these initial 
EPIC- PCD clinics, we will invite more PCD centres to join 
the study and begin patient recruitment.
Study procedures
Patient identification and recruitment
Eligible patients are identified and invited to participate 
in the study, and receive all study information by the 
local clinical team at the EPIC- PCD clinics. Patients are 
recruited during a clinical follow- up visit; there might 
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be small variations in recruitment and data collection 
between participating centres to allow the study to be 
embedded in the regular clinical routine.
Clinical assessments
Eligible patients are followed regularly at the EPIC- PCD 
clinics, at 3–6- month intervals, as planned for clinical 
reasons, regardless of their participation in the study. 
Each patient undergoes a detailed sinonasal and otologic 
examination by ENT specialists, at minimum once a year, 
during a scheduled follow- up visit. Additional ENT exam-
inations are performed on clinical indication in- between 
follow- up visits. Patients will not be subjected to addi-
tional invasive measurements solely for the purposes of 
the study; examinations and tests are only done if clini-
cally indicated or as part of the local follow- up protocol. 
All examinations and tests are performed following the 
local standard operating procedures of the clinic. The 
extended study team discusses differences and ensures 
that collected data are standardised and comparable.
Data collection instruments
For the collection of patient data, we use standardised 
PCD- specific instruments, specifically FOLLOW- PCD and 
QoL- PCD.
FOLLOW-PCD
It is a disease- specific form for standardised prospec-
tive data collection during routine clinical follow- up 
of patients with PCD.31 It was developed by a multidis-
ciplinary, international working group of the better 
experimental approaches to treat PCD (BEAT- PCD) 
COST action network.28 32 FOLLOW- PCD has a modular 
structure, which permits different members of the clin-
ical team (pulmonologists, ENT physicians, diagnostic 
experts, physiotherapists, lung function technicians, etc) 
to complete different modules. FOLLOW- PCD consists of 
seven modules that enable an extensive evaluation at base-
line and annual reviews, when all modules are completed, 
and a shorter evaluation at routine (eg, 3 monthly) 
follow- up, where only a few modules are used. For the 
EPIC- PCD study, we use specific modules to collect clin-
ical data relevant to the study, particularly demographic 
and diagnostic information, results of the physical ENT 
examination, results of clinical tests and data on hospital-
isations and treatments related to the upper airways.
Some modules of FOLLOW- PCD have been developed 
into patient questionnaires (FOLLOW- PCD question-
naire) that can be completed by the patients during each 
clinical follow- up visit. The FOLLOW- PCD questionnaire 
includes detailed questions on frequency and severity of 
upper and lower respiratory symptoms and health- related 
behaviours (eg, smoking and exercise).31 There are three 
age- specific versions of the questionnaires: one for adult 
patients, one for adolescents 14–18 years old and one for 
the parents or caretakers of patients aged less than 14 
years. The FOLLOW- PCD questionnaire has been orig-
inally developed in English, German and Greek and is 
translated in additional languages using a standardised 
procedure.
In addition to the FOLLOW- PCD questionnaire, we will 
ask the patients to complete once a year the QoL- PCD, a 
disease- specific, health- related QoL instrument for PCD, 
validated and translated in several languages.33–36 There 
are four different versions available for (a) children 
Figure 1 Centres currently participating to the EPIC- PCD cohort study. The EPIC- PCD clinics are marked with a black dot 
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(6–12 years), (b) adolescents (13–17 years), (c) adults 
(≥18 years) and (d) a parent- proxy measure for children 
≤12 years. The different versions of the questionnaire are 
divided into 7–10 hypothesised scales generated by multi-
trait analysis. All versions include two scales about upper 
respiratory symptoms, and ears and hearing symptoms, 
which are particularly relevant to this project. The QoL- 
PCD has demonstrated good internal consistency and 
test–retest reliability, and is a valuable tool for observa-
tional and interventional studies in PCD.
The FOLLOW- PCD questionnaire does not address 
QoL; therefore, the two questionnaires provide important 
complimentary information. Both questionnaires have 
been translated in the local language of each partici-
pating EPIC- PCD clinics.
Lastly, some centres use as part of their regular patient 
follow- up the Sino- Nasal Outcome Test- 22 (SNOT- 22) 
questionnaire that assess sinusitis- related QoL.37 In these 
centres, we will also record the SNOT- 22 score at baseline 
and at follow- up for all participating patients.
What information is collected
Figure 2 provides a brief overview of the information 
collected from participating patients at the baseline and 
follow- up visits, including the minimum required data, 
which are assessed for all patients in all participating 
centres and additional data from tests performed in 
few centres and which will be collected if available for 
subgroup analysis to address additional research ques-
tions. Small exemptions are allowed when a minimally 
required examination was not performed due to, for 
example, the patient’s very young age, as long as each 
patient undergoes a specialised ENT examination at least 
once a year.
ENT examinations
The ENT examinations performed in the participating 
centres in addition to physical examination include nasal 
endoscopy (either rigid or flexible), nasal function tests 
(eg, patency and olfaction) tests, tympanometry, audi-
ometry and auditory brainstem evoked response. Nasal 
endoscopy, tympanometry and audiometry are performed 
regularly at all centres during follow- up and belong to the 
minimum requirements for participation to the study; the 
remaining tests are performed only in selected, special-
ised centres either at initial diagnosis or during follow- up. 
When clinically indicated, patients will undergo CT of the 
sinuses or the ears. When available, we will collect data of 
previous imaging examinations of the sinuses or the ears 
from clinical records.
The data collected during the ENT examinations are 
predefined based on the ENT examinations module of 
the FOLLOW- PCD standardised form.31 Nasal endos-
copy data include the presence and consistency of nasal 
discharge (eg, serous and mucopurulent), evaluation of 
nasal mucosa (eg, presence of erythema or oedema), 
visual evaluation of nasal polyps using the Lildholdt 
score,38 evaluation of hypertrophy or atrophy of nasal 
turbinates and description of septum and any deformities 
caused due to chronic infection. Otoscopy data include 
the presence and consistency of ear discharge, visual 
description of the tympanic membrane (eg, tympanic 
perforation, retracted membrane and tympanic sclerosis) 
and the presence of acute otitis media or OME. Results 
of tympanometry are recorded using the description of 
tympanogram type by Jerger and of audiometry using the 
type of audiometry and the WHO hearing loss grades.39 
In addition, we record the presence of grommets or use 
of hearing aids. When sinus imaging is performed, we 
record the following findings: the presence of aplasia, 
Figure 2 Overview of the information collected during the EPIC- PCD cohort study. ENT, ear–nose–throat; EPIC- PCD, ear–
nose–throat prospective international cohort of patients with primary ciliary dyskinesia; SNOT- 22, Sino- Nasal Outcome Test- 22.
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hypoplasia, thickening of the bone and Lund- Mackay 
score.40
Other data from clinical records
At recruitment, baseline medical information and results 
of diagnostic tests will be extracted from clinical records 
and recorded using FOLLOW- PCD. In addition to the 
medical data from the upper airways, we collect data from 
lung function measurements, including spirometry and 
when available multiple breath- washout measurements 
and lung imaging. This information will allow us to assess 
associations between upper and lower respiratory disease 
in PCD.
On indication, nasopharyngeal or nasal swab samples, 
and when possible middle meatal samples, and sputum 
or cough samples for microbiological cultures and results 
will be collected. In case of otorrhoea, ear drainage 
samples will also be taken. We record the type of sample, 
the isolated pathogens and antibiotic resistance. We 
also collect information related to hospitalisations and 
surgical procedures related to upper airways disease and 
data on upper airway management.
Information from questionnaires
Participating patients are asked to complete the 
FOLLOW- PCD questionnaire at every visit and the QoL- 
PCD questionnaire at least once a year, as described earlier. 
The FOLLOW- PCD questionnaire includes sections on 
upper and lower respiratory symptoms, health- related 
behaviours (eg, exercise and smoking) and environ-
mental factors. The QoL- PCD questionnaire assesses how 
the disease affects the QoL of patients with PCD.
Study database
All collected data are entered into a secure web- based 
database using the database programme, Research Elec-
tronic Data Capture (REDCap) hosted by the Clinical 
Trials Unit, Bern.41 REDCap is widely used in academic 
research and allows data entry and extraction in various 
formats. Contributing centres are responsible for the 
pseudonymisation of the data contributed to the study. 
Only limited research staff from the EPIC- PCD data team 
has access to the whole dataset; local investigators at the 
EPIC- PCD clinics have access only to data from their 
clinic (box 1). Data generation, transmission, storage and 
analysis of health- related personal data within the study 
follow the Swiss legal requirements for data protection. 
All study team members are trained on data protection 
and dealing with particularly sensitive data.
Study power and sample size
We expect to recruit at least 450–550 patients in EPIC- PCD. 
This number is based on the study feasibility and the 
number of patients followed- up in the EPIC- PCD clinics 
and is considered large enough for a prospective study 
in such a rare disease and much larger than any other 
available PCD dataset on ENT disease. After the establish-
ment of the cohort, it is now possible for more centres 
to join and contribute patients, resulting in even higher 
numbers of patients. The planned analyses are up to a 
point exploratory and do not follow specific hypotheses, 
although we have few assumptions based on the limited 
literature. This does not allow for a precise power calcu-
lation; however, we will ensure that each performed anal-
ysis has sufficient power to draw meaningful conclusions.
Planned analysis and outcomes of interest
First, we will describe prevalence and severity of ENT 
problems, stratified by age, age at diagnosis, sex, country, 
ciliary ultrastructural defect or genetic mutation. 
Outcomes of interest will be sinonasal and otologic symp-
toms and signs (eg, rhinitis, loss of smell, sinusitis, otitis 
and impaired hearing) and the results of ENT examina-
tions (mainly of nasal endoscopy, tympanometry, audi-
ometry and when available imaging and SNOT- 22). We 
will estimate prevalence of binary outcomes and mean 
values of continuous outcomes by using constant- only 
models. We will use logistic regression models for binary 
outcomes, and linear models for continuous outcomes. 
Associations with determinants will be assessed in multi-
variable mixed models.
As a second step, we will assess the association of baseline 
ENT problems with lung disease progression expressed 
Box 1 Contributing to and accessing data in the EPIC- 
PCD
How to contribute data
 ► Centres that wish to participate in the project and contribute data 
can contact the EPIC- PCD data team. As soon as ethical approval 
is obtained and centre representatives have signed a data deliv-
ery agreement, they will receive a password to access the online 
software REDCap and they will be able to enter their data directly 
prospectively. We offer information and technical support wherever 
needed.
How to access data
 ► Participating centres keep constant access to their datasets and 
can export them directly in various formats for local analyses. 
Participating centres may also extract their datasets and contribute 
relevant data to other multinational projects or to the international 
PCD registry.
 ► The use of EPIC- PCD data from several centres for studies and pub-
lications is regulated by the EPIC- PCD committee, which consists of 
members of the EPIC- PCD data centre and representatives of the 
EPIC- PCD clinics. A series of publications are originally planned to 
be led by the EPIC- PCD data team, as part of the research grant 
funding the set- up and management of the study.
 ► For additional publications, collaborators should submit a concept 
sheet describing the planned analysis and publication to the com-
mittee, which will approve or oppose the planned publication and 
use of data. If the planned analysis is approved, a publication agree-
ment will be signed and the EPIC- PCD data centre will prepare a 
partial dataset for the proposed analysis and will work closely with 
the lead researchers of each planned study for methodological input 
and support.
 ► For further details, contact: myrofora.goutaki@ispm.unibe.ch.
EPIC- PCD, ear–nose–throat prospective international cohort of patients with 
PCD; REDCap, Research Electronic Data Capture.
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in terms of lung function tests, sputum cultures and, if 
available, lung imaging results. For this analysis, lung 
function will be the main outcome, measured primarily 
with spirometry and plethysmography measuring forced 
expiratory vital capacity and forced expiratory volume 
in 1 s. Data will be converted into z- scores adjusted for 
sex, height, age and ethnicity, using the Global Lung 
Initiative reference values. In some centres, PCD patients 
also perform multiple breath washout measurements at 
follow- up, which have been reported to be more sensi-
tive in detecting early lung disease. In those patients, 
Lung Clearance Index will be considered as a secondary 
outcome, if patients’ numbers allow it. We will use mixed 
models, including the baseline ENT disease characteris-
tics with an interaction of each with age as fixed effects, 
and the patients and the centres as random effects.
Finally, we will analyse follow- up data on ENT symptoms 
and examinations to describe the short- term course of 
sinonasal and otologic disease during a 2- year follow- up, 
and identify determinants of disease prognosis. Here, 
outcomes of interest will be the severity of CRS (based 
on a symptoms score), loss of smell, bacterial colonisation 
of the upper respiratory tract, need of surgical manage-
ment of the sinuses, recurrent otitis media, OME, hearing 
impairment and need of surgical management of the ears. 
We will first describe how the outcomes change over the 
follow- up time in binomial or multinomial (for outcomes 
with more than three categories, such as hearing impair-
ment) mixed models, using separate models for each 
outcome. Then, we will study determinants of disease 
prognosis categorising patients in four groups for each 
outcome based on the evaluation at baseline and at 2- year 
follow- up: (a) patients who never reported the outcome, 
(b) patients negative for the outcome at baseline but 
positive at follow- up, (c) patients positive at baseline but 
negative at follow- up and (d) patients positive at both 
time points. We will use mixed- effects multinomial regres-
sion models, including all possible determinants as fixed 
effects. We will select possible determinants from char-
acteristics available at baseline, including symptoms and 
measurements; age at diagnosis, ultrastructural defects 
and genetic mutations; and general patient characteris-
tics, such as age and sex. We will make our determinants 
selection based on directed acyclic graphs, considering 
existing literature. Data will be collected prospectively 
and in a standardised way resulting in small data heteroge-
neity between participating centres; however, we will still 
need to account for possible differences between coun-
tries in all analyses. Thus, we will analyse all outcomes 
of interest using random- effects models that account for 
clustering of patients within participating centres.
For all analyses, results will be interpreted with caution 
considering the clinical importance and not just mere 
statistically significant findings. If needed, we will correct 
for multiple testing. All missing values will be described 
in detail; however, we expect this will not be an issue for 
the important variables as the data are collected prospec-
tively. In case we have significant amount of missing data, 
we will consider subgroup analyses or multiple imputa-
tion of missing data to deal with this issue, depending on 
what is the most appropriate approach for the specific 
question and analysis.
ETHICS AND DISSEMINATION
Ethical approval to share pseudoanonymised patient 
data was obtained locally at each participating centre 
(online supplemental file). Written informed consent 
will be obtained in accordance with the national/local 
data protection laws, from patients aged 14 years or more 
(might differ per country based on local laws) or from 
the patient’s parents/caregivers for younger patients. 
Patients can withdraw their consent and their data from 
the study at any time by contacting the clinical team at 
each participating centre.
The results of the study will be published in scientific 
journals and presented at scientific conferences to raise 
awareness about upper respiratory disease in patients 
with PCD.
The principal investigator of the study affirms and 
upholds the principle of the participants’ right to dignity, 
privacy and health and that the project team shall comply 
with applicable privacy laws. Especially, anonymity of the 
participants shall be guaranteed when presenting the 
data at scientific meetings or publishing them in scien-
tific journals. Individual participant medical information 
obtained during this research project is considered confi-
dential and will not be disclosed to third parties. Data will 
not be deposited at an open access repository. Because 
of the rarity of the disease although data will be pseud-
onymised, it may include still sensitive information; there-
fore, participants will not be asked to give consent to have 
their data deposited publicly.
Patient and public involvement
Several patient support organisations were consulted and 
support the study. The EPIC- PCD is set up and can be 
further developed in the framework of the BEAT- PCD 
clinical research collaboration (CRC) network supported 
by the ERS.42 The BEAT- PCD CRC is a large multi-
disciplinary network, which includes more than 500 
researchers and clinicians from more than 30 countries. 
The EPIC- PCD is part of the BEAT- PCD research port-
folio, which ensures widespread dissemination of the 
study results to researchers, clinicians, patients and all 
relevant stakeholders. Additionally, the EPIC- PCD study 
team works closely with a team of patients with PCD who 
consult BEAT- PCD to ensure that all studies support their 
interests. Summaries of results in lay language will be 
disseminated to participants and national patient organ-
isations by the EPIC- PCD data centre and the EPIC- PCD 
clinics, and to the relevant stakeholders and the public 
through the BEAT- PCD CRC website and social media.
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